Related MeSH Hierarchy (5)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Pancreatic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Pancreatic Neoplasms
Diseases [C] » Digestive System Diseases [C06] » Pancreatic Diseases » Pancreatic Neoplasms
Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Pancreatic Neoplasms
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Pancreatic Neoplasms
Description
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). MeSH
Hierarchy View
Subtype Terms (4)
Adenoma, Islet Cell
21 drugs (19 approved, 2 experimental)
Carcinoma, Islet Cell
28 drugs (22 approved, 6 experimental)
Carcinoma, Pancreatic Ductal
27 drugs (15 approved, 12 experimental)
Pancreatic Intraductal Neoplasms
6 approved drugs
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (65)
Phase 2 Indicated Drugs (376)
177lu-dota0-tyr3-octreotate (Dotatate)
allogenic gm-csf plasmid-transfected pancreatic tumor cell vaccine
autologous dendritic cells loaded with autologous tumor lysate
autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine
autologous tumor infiltrating lymphocytes
Efbemalenograstim alpha (Ryzneuta)
erwinia asparaginase (Erwinaze)
gvax pancreatic cancer vaccine
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
interferon alpha-2a (roferon-a)
interferon alpha-2b (Intron-A)
interferon gamma-1b (actimmune)
Phase 1 Indicated Drugs (340)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic pancreatic tumor cells transfected with a gm-csf gene
autologous, engineered t cells targeting tp53 r175h
dendritic cell loaded with ofa
hepatitis b vaccine (recombinant) (Recombivax)
her2bi-armed activated t cells
hgm-csf herpes simplex virus injection
mesenchymal stromal cells-derived exosomes with kras g12d sirna
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
modified vaccinia virus ankara vaccine expressing p53
pancreatic tumor peptide-pulsed dendritic cells
personalized neoantigen vaccine
procaine benzylpenicillin (novocaine)
procaspase activating compound-1
prostate specific membrane antigen
recombinant fowlpox-cea(6d)/tricom vaccine
Other Experimental Indicated Drugs (48)
Organization Involved with Phase 4 Indications (26)
Organization Involved with Phase 3 Indications (201)
Academic Oncology Gastrointestinal Cancer Consortium
Advocate Illinois Masonic Medical Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Assistance Publique - Hôpitaux de Paris
Australasian Gastro-Intestinal Trials Group
Baptist Memorial Health Care Corporation
Biotech Pharmaceutical Co., Ltd.
Cancer and Leukemia Group B (CALGB)
Cancerforskningsfonden i Norrland
Central European Cooperative Oncology Group
Centre Hospitalier de Longjumeau, France
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
European Organisation for Research and Treatment of Cancer
Gottfried Wilhelm Leibniz Universität Hannover
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico Italia Meridionale
Gruppo Oncologico Italiano di Ricerca Clinica
Hackensack University Medical Center
Huazhong University of Science and Technology
Innovative Medical Research of South Florida, Inc
Istituti Tumori Giovanni Paolo II
Memorial Sloan-Kettering Cancer Center
National Cheng Kung University
National Heart, Lung, and Blood Institute (NHLBI)
Pancreatic Cancer Action Network
Pharmaceutical Research Associates, Inc. (PRA)
Radiation Therapy Oncology Group
Regional Cancer Centre Stockholm Gotland
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Signe & Ane Gyllenbergs Stiftelse
Swiss Group for Clinical Cancer Research
Technical University of Munich
The Christie NHS Foundation Trust
University Corporation for Atmospheric Research
University Hospital of North Norway
University of Alabama, Birmingham
University of California, Davis
University of Campania Luigi Vanvitelli
University of Erlangen-Nuremberg
University of Roma La Sapienza
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Organization Involved with Phase 2 Indications (410)
Academic and Community Cancer Research United
Advanced Accelerator Applications
American Association for Cancer Research
Asociación de Oncología Médica del Hospital de Cruces
Belarusian State Medical University
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Big Ten Cancer Research Consortium
British Columbia Cancer Agency
Cancer Treatment Centers of America
Case Western Reserve University
Central European Society for Anticancer Drug Research (CESAR)
Central India Cancer Research Institute, Nagpur
Changzhou No.2 People's Hospital
Chinese Academy of Medical Sciences
Chongqing Precision Biotech Co., Ltd
City of Hope National Medical Center
Clinica Universidad de Navarra
CNAO National Center of Oncological Hadrontherapy
COMPLEJO HOSPITALARIO REGIONAL VIRGEN DE LAS NIEVES
Curie Manavata Cancer Center, Nashik, India
Deenanath Mangeshkar Hospital & Research Centre
Developmental Therapeutics Consortium
Eastchester Center for Cancer Care
Grand Rapids Clinical Oncology Program
Grupo Espanol de Tumores Neuroendocrinos (GETNE)
Harris County Hospital District
Hellenic Cooperative Oncology Group
Hellenic Oncology Research Group
HonorHealth Research Institute
Hoosier Cancer Research Network
Hospital HM Universitario Sanchinarro
Hospital Universitario de Fuenlabrada
Hospital Universitario Madrid Sanchinarro
Infinity Pharmaceuticals, Inc.
Institut de Cancérologie de Lorraine
Institute for Developmental Cancer Therapeutics
Instituto do Cancer do Estado de São Paulo
Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Isala Clinics, Zwolle, The Netherlands
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
James Graham Brown Cancer Center
Japan Adjuvant Study Group of Pancreatic Cancer
Japan Agency for Medical Research and Development
Japan Clinical Cancer Research Organization
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Katholieke Universiteit Leuven
Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I
Lifeline Mutispecilaity Hospital, Chennai, India
Mecosta County General Hospital
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
National Cancer Institute, France
National Comprehensive Cancer Network
National Institutes of Health (NIH)
National University of Malaysia
New Mexico Cancer Care Alliance
North Central Cancer Treatment Group
Northeast Ohio Medical University
Oddzial Kliniczny Kliniki Onkologii
Oddzial Onkologii Klinicznej im L Rydygiera
Ontario Institute for Cancer Research
Oregon Health and Science University
Osaka Medical Center for Cancer and Cardiovascular Diseases
Pancreatic Cancer Research Team
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Professor Cunningham's Clinical Research Fund
Prologue Research International
Queen Elizabeth Hospital NHS Foundation Trust
Regionalny Szpital Specjalistyczny Latawiec
Riveria Country Club Organization
Royal Marsden Hospital NHS Trust
Salk Institute for Biological Studies
Seattle Cancer Treatment and Wellness Center
Shanghai Asclepius Meditec Inc.
Shenzhen Hank Bioengineering Institute
South Plains Oncology Consortium
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Sri Ramachandra Medical College, Chennai
State University of New York, Buffalo
St. Vincent Medical Center - Los Angeles
Susan L Bader Foundation of Hope
Taiwan Cooperative Oncology Group
The Republican Center for Research and Practice in Otolaryngology, Belarus
The Republican Research and Practical Center for Epidemiology and Microbiology
Tokyo Metropolitan Komagome Hospital
Translational Drug Development
Translational Oncology Research International
Trans Tasman Radiation Oncology Group
Universidad Autonoma de Barcelona
Universidad Complutense de Madrid
Universitario de Santiago, Spain
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Medicine and Dentistry of New Jersey
University of Naples Frederico II
University of North Carolina at Chapel Hill
University of Southern California
University of Southern Denmark
University of Texas, Galveston
University of Texas, San Antonio
Vall d'Hebron Institute of Research, Galatea Clinic
Wuhan Binhui Biotechnology Co., Ltd.
Organization Involved with Phase 1 Indications (104)
American Society for Gastrointestinal Endoscopy
Betta Pharmaceuticals Co.,Ltd.
BioMed Valley Discoveries, Inc
Charles A. Sammons Cancer Center/Texas Oncology
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hangzhou Neoantigen Therapeutics Co., Ltd.
Ichor Medical Systems Incorporated
Lotte & John Hecht Memorial Foundation
National Center for Complementary and Integrative Health (NCCIH)
North Shore Hospital, New Zealand
Samyang Biopharmaceuticals Corporation
Second Military Medical University
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Organization Involved with Other Experimental Indications (24)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
